| Total | Age at onset (n = 147) | Cumulative joints during the first eight years of disease (n = 147) | Remission after 8 years (n = 147) | Articular damage*** at eight year follow up (n = 147) | ||||
---|---|---|---|---|---|---|---|---|---|
 | n (%) | Median (IQR) | p* | Median (IQR) | p* | Number of patients without remission/total number (%) | p** | Number of patients with damage/total number (%) | p** |
Total cohort | 147 | 5.4 (2.8-9.9) |  | 8 (3–15) |  | 99/147 (67%) |  | 18/147 (12) |  |
IgM RF positive | 6 (4.1%) | 10.5 (13.0-13.4) | 0.002 | 8 (2–20) | 0.79 | 3/6 (50%) | 0.39 | 3/6 (50) | 0.0068 |
IgA RF positive | 6 (4.1%) | 11.4 (7.6-13.2) | 0.07 | 16 (4–18) | 0.57 | 1/6 (17%) | 0.66 | 4/6 (67) | 0.0001 |
Anti-CCP positive | 5 (3.4%) | 11.0 (6.0-12.6) | 0.15 | 18 (4–22) | 0.89 | 1/5 (20%) | 1.00 | 3/5 (60) | 0.0007 |
Anti-collagen II positive | 5 (3.4%) | 4.8 (4.2-11.4) | 0.54 | 13 (6–26) | 0.29 | 2/5 (40%) | 0.66 | 2/5 (40) | 0.0274 |
Any conventional# antibody | Â | Â | Â | Â | Â | Â | Â | 5/11 | 0.0004 |
Any antibody¤ |  |  |  |  |  |  |  | 6/15 | 0.0004 |